Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-Interventional, Prospective Observational Cohort Study to Investigate the Effectiveness and Sustained Disease Control of an Upadacitinib Therapy in Moderate to Severe Atopic Dermatitis Patients Over Two Years

Next Previous
X
Search
Trial Profile

Non-Interventional, Prospective Observational Cohort Study to Investigate the Effectiveness and Sustained Disease Control of an Upadacitinib Therapy in Moderate to Severe Atopic Dermatitis Patients Over Two Years

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms MEASURE-AD; UP-TAINED
  • Sponsors AbbVie

    • Most Recent Events

    • 10 Mar 2023 Planned End Date changed from 3 Jun 2025 to 30 Nov 2026.
    • 10 Mar 2023 Planned primary completion date changed from 3 Jun 2025 to 30 Nov 2026.
    • 29 Aug 2022 According to an Abbvie media release, data from the trial will be presented in a late-breaking oral presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top